Free beta- human chorionic gonadotropin, total human chorionic gonadotropin and maternal risk of breast cancer
2014 (English)In: Future Oncology, ISSN 1479-6694, E-ISSN 1744-8301, Vol. 10, no 3, 377-384 p.Article in journal (Refereed) Published
Background: We investigated whether the free -human chorionic gonadotropin (free -hCG) would provide additional information to that provided by total hCG alone and thus be useful in future epidemiological studies relating hCG to maternal breast cancer risk. Materials & methods: Cases (n = 159) and controls (n = 286) were a subset of our previous study within the Northern Sweden Maternity Cohort on total hCG during primiparous pregnancy and breast cancer risk. Results: The associations between total hCG (hazard ratio: 0.79; 95% CI: 0.49-1.27), free -hCG (hazard ratio: 0.85; 95% CI: 0.33-2.18) and maternal risk of breast cancer were very similar in all analyses and mutual adjustment for either one had minor effects on the risk estimates. Conclusion: In the absence of a reliable assay on intact hCG, total hCG alone can be used in epidemiological studies investigating hCG and breast cancer risk, as free -hCG does not appear to provide any additional information.
Place, publisher, year, edition, pages
2014. Vol. 10, no 3, 377-384 p.
breast cancer, free -human chorionic gonadotropin, human chorionic gonadotropin, nested case-control study, pregnancy
Cancer and Oncology
IdentifiersURN: urn:nbn:se:umu:diva-90464DOI: 10.2217/FON.13.208ISI: 000331698600011OAI: oai:DiVA.org:umu-90464DiVA: diva2:733008